

ATHERSYS, INC / NEW
Form 8-K
January 08, 2013

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 7, 2013

ATHERSYS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction of
Incorporation)

001-33876
(Commission
File Number)

20-4864095
(IRS Employer
Identification No.)

Edgar Filing: ATHERSYS, INC / NEW - Form 8-K

3201 Carnegie Avenue,

Cleveland, Ohio

(Address of Principal Executive Offices)

Registrant's telephone number, including area code: (216) 431-9900

44115-2634

(Zip Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On January 7, 2013, the Board of Directors of Athersys, Inc. (the *Company*), upon the recommendation of the Compensation Committee of the Board of Directors of the Company, approved the following cash bonuses to the named executive officers of the Company, based on individual performance and achievement of corporate goals in 2012:

Name	Title	Award
Dr. Gil Van Bokkelen	Chief Executive Officer	\$ 107,500
William Lehmann, Jr.	President and Chief Operating Officer	\$ 77,000
Dr. John Harrington	Executive Vice President and Chief Scientific Officer	\$ 77,800
Dr. Robert Deans	Executive Vice President, Regenerative Medicine	\$ 62,300
Laura Campbell	Vice President of Finance	\$ 40,500

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ATHERSYS, INC.

By: /s/ Laura K. Campbell
Name: Laura K. Campbell
Title: Vice President of Finance

Date: January 8, 2013